A naukri.com initiative
Bioengineer
4d
117
Image Credit: Bioengineer
Experimental Drug Development Centre Reveals Updated Phase 1 Data on Antibody-Drug Conjugate EBC-129 at ASCO 2025
- The Experimental Drug Development Centre in Singapore presents updated Phase 1 data on the antibody-drug conjugate EBC-129 targeting pancreatic cancer at ASCO 2025.
- EBC-129, a novel antibody-drug conjugate, targets a unique N256-glycosylated epitope on CEACAM5 and CEACAM6 in pancreatic cancer.
- The Phase 1 trial update, discussed at ASCO 2025, shows promising results in heavily pretreated pancreatic cancer patients.
- EBC-129 demonstrated specificity and potency, with efficacy in terms of overall response rates, disease control rates, and progression-free survival.
- Safety assessments indicate manageable adverse events, primarily neutropenia and infusion-related reactions.
- The antigen targeted by EBC-129 is found in various solid tumors, hinting at broader applicability beyond pancreatic cancer.
- The drug's payload, monomethyl auristatin E, facilitates targeted cytotoxicity with potential synergistic effects in combination therapy.
- EBC-129's Fast Track Designation by the FDA highlights the urgent unmet need in pancreatic cancer treatment and supports expedited development.
- Experts acknowledge the therapeutic promise of EBC-129, particularly in refractory pancreatic cancer patients resistant to standard treatments.
- The ongoing clinical development of EBC-129 with a focus on intensified biology-guided trials and innovative diagnostic tools sets a promising course in oncology therapeutics.
Read Full Article
7 Likes
For uninterrupted reading, download the app